MedTrace Logo

Disease-Modifying Treatments for Myasthenia Gravis

NCT03490539 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 167

Last updated 2021-02-03

No results posted yet for this study

Summary

This study is designed to address the evidence gaps in a real-world setting and help patients with MG choose treatments that are best suited to them. It is a prospective, multicenter observational cohort study of comparative effectiveness of MG treatments, with a patient-centered primary outcome measure, to guide clinicians, patients and payers regarding the choice of treatment options for this chronic and serious disease.

Primary: To compare the effectiveness of azathioprine (AZT) and mycophenolate mofetil (MMF).

Secondary: To compare the outcomes in patients receiving an adequate dose and duration of AZT or MMF over the 2-3 year study period, vs. patients not receiving adequate doses and duration of these agents

Conditions

Interventions

DRUG

Mycophenolate Mofetil

oral tablets

DRUG

Azathioprine

oral tablet

Sponsors & Collaborators

Principal Investigators

  • Jeffery Guptill, MD · Duke University

  • Donald Sanders, MD · Duke University

  • Pushpa Narayanaswami, MD · Beth Israel Deaconess Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03490539 on ClinicalTrials.gov